Key facts
- Notable investors include SJ Investment Partners, Ulmus Investment, Hyundai Venture Investment Corporation, AJU IB Investment, Genaxis (Korea) — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Engain
- ·The full record, as it builds
Funding rounds
No funding rounds for Engain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Engain
Developer of specialized healthcare technology designed to localize and improve therapeutic products and diagnostic technologies. The company's technology includes a color change sensing platform in the field of color change detection, as well as products for treating varicose veins and disposable medical consumables through color transfer materials, medical adhesives and vascular bonding, enabling healthcare professionals to have new specialized medical devices.
- Sector
- Healthcare
- HQ
- Hwaseong, South Korea
- Founded
- 2011
- Employees
- 32
- Website
- engain.co.kr/
- Ownership
- Privately Held (backing)
Engain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Engain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Engain in its N-PORT filings yet. We sweep new filings monthly.